14th Tumour Models London Summit

With the European oncology market increasingly focused on emerging modalities, highlighted by AbbVie’s recent licensing agreement with Ichnos Glenmark Innovation for their trispecific antibody, Boehringer Ingelheim’s partnership with Tempus to advance their cancer pipeline and the FDA’s new roadmap and the EMA encouraging drug developers to use non-animal tests in submissions, there has never been a more important year to stay up to date with the latest innovations in tumour modelling.

As the longest-standing forum from the world-renowned Tumour Models event series, the 14th Tumour Models Summit London returns to unite 130+ tumour modelling experts from pharma, biotech, and model providers from across the UK and Western Europe to soundboard recent model selection strategies with the goal of bridging the translational gap to the clinic.


URLs:
Website: https://go.evvnt.com/3229772-0?pid=2874
Brochure: https://go.evvnt.com/3229772-3?pid=2874

Category: Conferences | Health

Prices:
Conference Only - Drug Developers and Researchers Pricing: GBP 0.50,
Conference Only - Service Provider/Vendor Pricing: GBP 3199.00

Speakers: Suzanne Sitnikova, Director, AstraZeneca, Michiel Plugge, Director of Welfare and Compliance, AstraZeneca, Victoria Juskaite, Principal Scientist Therapeutics, Avacta, Ludovic Bigot, Project Manager, Gustave Roussy, Christian Orlik, Associate Director In vitro Biology, Heidelberg Pharma, Elisabeth Wieduwild, Scientist, ImCheck Therapeutics, Florence Meyer-Losic, Vice President Head of Translational Sciences, Ipsen Pharma, Ronnie Chamanza, Scientific Director Pathology, Johnson and Johnson, Frederic Pipp, Global Animal Welfare Officer EMEA AND APAC, Merck KGaA, Peter Ashcroft, Principal Scicentist II, Novartis, Víctor Díaz, Head of Research, OneChain Immunotherapeutics, Nicholas Glanville, Vice President Research, Prokarium, Niina Veitonmäki, Supervisor Immunooncology, Pure Biologics, Stefaan Verbruggen, Lecturer in Medical Technology, Queen Mary University of London, Simon Woodcock, Vice President and Head of Biology, RedX Pharma, Sara Colombetti, Head of Global Department, Roche, Claudio Murgia, Group Leader - In Vivo Pharmacology, Roche, Manel Merabet, Chief Development Officer, Skymab Biotherapeutics, Dinis Calado, Senior Group Leader, The Francis Crick Institute, Thomas Baumert, Professor of Medicine, Chair and Institute Head, University of Strasbourg